Adaptive Biotech Q2 revenue up 12% to $48.9M; net loss narrows; MRD chief exits

Adaptive Biotechnologies Corp

2023-Q2 EPS reported -$0.73 revenue$86,573,000

Revenue $48.9M (+12% YoY); MRD revenue $25.9M (+22%); Immune Medicine $23.0M (+3%).
clonoSEQ test volume +52% to 13,665 tests delivered.
Net loss $47.8M vs $52.1M YoY; adjusted EBITDA loss $24.8M vs $33.1M.
Full-year 2023 revenue guidance reiterated at $205-215M; operating expenses expected below 2022's $385.5M.
Nitin Sood, Chief Commercial Officer of MRD, resigns effective Aug 15; Susan Bobulsky assumes additional responsibilities, reports to CEO.

item 2.02 item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Nitin Sood

Chief Commercial Officer of the MRD business

ADPT · Adaptive Biotechnologies Corp

Effective: 2023-08-15
Filed: August 2, 2023, 7:59 PM ET

On July 28, 2023, the Company's Chief Commercial Officer of the MRD business, Nitin Sood, resigned to pursue a new opportunity.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Adaptive Biotechnologies Corp reported the quarter ended June 30, 2023 results: revenue $48.9 million, net income $47.8 million. Guidance reaffirmed.

Period: the quarter ended June 30, 2023
Revenue: $48.9 million
Net income: $47.8 million
Guidance: reaffirmed
Result: reported results

Exact text from the filing

Immune Medicine businesses and we remain committed to driving operational efficiencies across the company while supporting sustainable growth.” Recent Highlights • Revenue of $48.9 million for the second quarter 2023, representing 12% growth from $43.7 million in the second quarter 2022. • clonoSEQ test volume in the second quarter 2023 grew 52% to 13,665 tests

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Nitin Sood resigned as Chief Commercial Officer of the MRD business at Adaptive Biotechnologies Corp.

Action: resigned
Role: Chief Commercial Officer of the MRD business

Exact text from the filing

On July 28, 2023, the Company's Chief Commercial Officer of the MRD business, Nitin Sood, resigned to pursue a new opportunity.

View on SEC.gov

Browse all earnings releases →

Adaptive Biotechnologies Corp filing history →

Source: SEC EDGAR

accession 0000950170-23-037192

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.